See more : Uni-Bio Science Group Limited (0690.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Emerald Health Therapeutics, Inc. (EMHTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Emerald Health Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Intapp, Inc. (INTA) Income Statement Analysis – Financial Results
- JBM Auto Limited (JBMA.NS) Income Statement Analysis – Financial Results
- Legacy Education Inc. (LGCY) Income Statement Analysis – Financial Results
- AYM Syntex Limited (AYMSYNTEX.BO) Income Statement Analysis – Financial Results
- Reconnaissance Energy Africa Ltd. (RECAF) Income Statement Analysis – Financial Results
Emerald Health Therapeutics, Inc. (EMHTF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://emeraldhealth.ca
About Emerald Health Therapeutics, Inc.
Emerald Health Therapeutics, Inc., together with its subsidiaries, engages in the production, distribution, and sale of recreational and medical cannabis in Canada. It offers dried cannabis strains, pre-rolled cannabis, oral sprays, nano emulsion shots, and cannabis oil products under the SYNC Wellness, fuse, Emerald, and Souvenir brands. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada. As of November 10, 2022, Emerald Health Therapeutics, Inc. operates as a subsidiary of Skye Bioscience, Inc.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.68M | 11.74M | 20.32M | 1.95M | 937.65K | 253.32K | 31.29K | 0.00 | 117.55K | 233.74K | 46.57K | 0.00 | 0.00 |
| Cost of Revenue | 16.14M | 21.41M | 34.79M | 5.05M | 1.22M | 603.27K | 203.80K | 0.00 | 53.18K | 94.17K | 17.25K | 0.00 | 0.00 |
| Gross Profit | -6.46M | -9.67M | -14.47M | -3.10M | -285.52K | -349.95K | -172.51K | 0.00 | 64.37K | 139.57K | 29.32K | 0.00 | 0.00 |
| Gross Profit Ratio | -66.72% | -82.37% | -71.21% | -159.06% | -30.45% | -138.14% | -551.31% | 0.00% | 54.76% | 59.71% | 62.96% | 0.00% | 0.00% |
| Research & Development | 1.73M | 1.57M | 4.28M | 801.35K | 207.50K | 301.53K | 162.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.92M | 12.44M | 26.04M | 21.49M | 7.89M | 1.90M | 2.76M | 1.88M | 94.87K | 77.47K | 60.25K | 26.42K | 63.62K |
| Selling & Marketing | 2.37M | 1.56M | 4.37M | 11.33M | 428.54K | 271.12K | 360.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.29M | 14.00M | 30.41M | 32.83M | 8.32M | 2.17M | 3.12M | 1.88M | 94.87K | 77.47K | 60.25K | 26.42K | 63.62K |
| Other Expenses | 1.25M | 1.76M | 1.85M | 618.44K | 282.45K | 116.35K | 46.41K | 20.19K | 57.97K | 70.02K | 14.30K | 0.00 | 0.00 |
| Operating Expenses | 14.27M | 17.33M | 36.54M | 34.25M | 8.81M | 2.59M | 3.32M | 1.90M | 152.84K | 147.49K | 74.55K | 26.42K | 63.62K |
| Cost & Expenses | 30.41M | 38.74M | 71.33M | 39.29M | 10.03M | 3.19M | 3.53M | 1.90M | 206.01K | 241.66K | 91.80K | 26.42K | 63.62K |
| Interest Income | 298.00K | 1.28M | 952.88K | 1.19M | 161.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 451.00 | 1.90K |
| Interest Expense | 700.00K | 4.97M | 765.64K | 218.60K | 0.00 | 39.68K | 0.00 | 0.00 | 52.08K | 63.04K | 13.00K | 154.00 | 0.00 |
| Depreciation & Amortization | 2.85M | 4.82M | 6.43M | 3.45M | 282.45K | 116.35K | 46.41K | 20.19K | 61.66K | 70.02K | 14.30K | 605.00 | 1.90K |
| EBITDA | -35.61M | -32.96M | -105.81M | -26.93M | -8.45M | -2.78M | -3.45M | -2.62M | -30.50K | 62.10K | -30.93K | -25.97K | -61.83K |
| EBITDA Ratio | -367.94% | -280.78% | -520.74% | -1,382.37% | -901.12% | -1,099.19% | -11,028.29% | 0.00% | -25.94% | 26.57% | -66.41% | 0.00% | 0.00% |
| Operating Income | -38.47M | -37.78M | -112.24M | -30.38M | -8.73M | -2.90M | -3.50M | -2.65M | -92.16K | -7.93K | -45.23K | -26.58K | -63.73K |
| Operating Income Ratio | -397.43% | -321.83% | -552.38% | -1,559.31% | -931.24% | -1,145.12% | -11,176.60% | 0.00% | -78.40% | -3.39% | -97.11% | 0.00% | 0.00% |
| Total Other Income/Expenses | -700.00K | -5.56M | -164.02M | -625.12K | -109.99K | -39.68K | 0.00 | 0.00 | -52.08K | -63.04K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -39.17M | -43.34M | -113.01M | -31.01M | -8.84M | -2.94M | -3.50M | -2.65M | -144.24K | -70.97K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -404.66% | -369.19% | -556.15% | -1,591.39% | -942.97% | -1,160.78% | -11,176.60% | 0.00% | -122.70% | -30.36% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 700.00K | 196.00K | -1.10M | -23.61K | -109.99K | 39.68K | 0.00 | 0.00 | 52.08K | 63.04K | 13.00K | -605.00 | -1.90K |
| Net Income | -39.87M | -43.54M | -111.91M | -30.98M | -8.73M | -2.98M | -3.50M | -2.65M | -196.32K | -134.01K | -58.22K | -25.97K | -61.83K |
| Net Income Ratio | -411.89% | -370.86% | -550.74% | -1,590.18% | -931.24% | -1,176.44% | -11,176.60% | 0.00% | -167.01% | -57.33% | -125.02% | 0.00% | 0.00% |
| EPS | -0.21 | -0.23 | -0.76 | -0.22 | -0.10 | -0.05 | -0.08 | -0.07 | -0.10 | -0.07 | -0.03 | -0.05 | -0.21 |
| EPS Diluted | -0.21 | -0.23 | -0.76 | -0.22 | -0.10 | -0.05 | -0.08 | -0.07 | -0.10 | -0.07 | -0.03 | -0.05 | -0.21 |
| Weighted Avg Shares Out | 193.21M | 193.21M | 147.96M | 141.44M | 88.45M | 54.26M | 46.07M | 37.08M | 2.01M | 2.01M | 2.00M | 487.20K | 298.60K |
| Weighted Avg Shares Out (Dil) | 193.21M | 193.21M | 147.96M | 141.44M | 88.45M | 54.26M | 46.07M | 37.08M | 2.01M | 2.01M | 2.00M | 487.20K | 298.60K |
Emerald Health Therapeutics Retains Listing Agent to Sell Previously-Closed Greater Vancouver Cannabis Cultivation Facility
Vancouver, British Columbia--(Newsfile Corp. - July 23, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has retained BC Farm & Ranch Realty Corp., a real estate agent dedicated 100% to agricultural properties, to assist in the sale...
Emerald Health Therapeutics Licenses New Proprietary Cannabis Dried Flower Format Patent for use in United States
Emerald secures equity position in US company launching unique cannabis specialty productVancouver, British Columbia--(Newsfile Corp. - May 6, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has entered into a license agreement (the "Agreement") with FlowerPod LLC...
Emerald Health Therapeutics Appoints Moe Jiwan as Chief Operating Officer
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has appointed Mr. Moe Jiwan as Chief Operating Officer effective May 10th.Mr. Jiwan is a data-driven business leader with over 20 years of...
Emerald Health Therapeutics, Inc. (EMHTF) CEO Riaz Bandali on Q4 2020 Results - Earnings Call Transcript
Emerald Health Therapeutics, Inc. (EMHTF) CEO Riaz Bandali on Q4 2020 Results - Earnings Call Transcript
Emerald Health Therapeutics Reports 2020 Year-end and Fourth Quarter Financial Results and Provides Corporate Update
Emerald hosting conference call today, May 3rd, at 10:30 am ETVancouver, British Columbia--(Newsfile Corp. - May 3, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has released its financial results for the 12 months ended December 31,...
Emerald Health Therapeutics Confirms Effective Listing Date on Canadian Securities Exchange
Emerald to host 2020 year-end financial results conference call on Monday, May 3, 2021, at 10:30 AM ETVancouver, British Columbia--(Newsfile Corp. - April 23, 2021) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald" or "the Company") has received...
Emerald Health Therapeutics Establishes Partnership with Spanish Greenhouse Grower for GMP-Certified Cannabis
Vancouver, British Columbia--(Newsfile Corp. - March 17, 2021) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") has formed a partnership with Medical Plants SLU, based in Almeria, Spain, in which it will provide resources and expertise to assist...
Emerald Health Therapeutics to Close Greater Vancouver Production Facility
Vancouver, British Columbia--(Newsfile Corp. - February 18, 2021) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") today announced that it will cease operations at its cannabis production facility in Greater Vancouver, British Columbia effective March 31, 2021 and...
Emerald Health Therapeutics Receives $20.5M Payment from Village Farms and Outlines Growth Plans
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2021) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") has received from Village Farms International Inc. $19.9M plus $621,534.25 in interest, representing full repayment of the promissory note issued by Village...
Emerald Health Therapeutics Promotes Two Executives to Senior Roles
Vancouver, British Columbia--(Newsfile Corp. - February 5, 2021) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") has promoted Orville Bovenschen to the position of Senior Vice President, Operations and Rebecca Wong to Senior Vice President, Quality & Regulatory...
Source: https://incomestatements.info
Category: Stock Reports